These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10680149

  • 1. Paclitaxel in the treatment of advanced urothelial cancer.
    Bajorin DF.
    Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149
    [Abstract] [Full Text] [Related]

  • 2. Review and outlook for the role of paclitaxel in urothelial carcinoma.
    Vaughn DJ.
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
    [Abstract] [Full Text] [Related]

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Feb; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 4. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y.
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [Abstract] [Full Text] [Related]

  • 5. Overview of bladder cancer trials in the European Organization for Research and Treatment.
    de Wit R, European Organization for Research and Treatment.
    Cancer; 2003 Apr 15; 97(8 Suppl):2120-6. PubMed ID: 12673705
    [Abstract] [Full Text] [Related]

  • 6. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer.
    Hainsworth JD, Greco FA.
    Semin Oncol; 1999 Feb 15; 26(1 Suppl 2):60-6. PubMed ID: 10190785
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 15; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
    Vaughn DJ.
    Cancer Treat Rev; 2008 Jun 15; 34(4):328-38. PubMed ID: 18262363
    [Abstract] [Full Text] [Related]

  • 10. The role of ifosfamide in the treatment of testicular and urothelial malignancies.
    Roth BJ.
    Semin Oncol; 1996 Jun 15; 23(3 Suppl 7):19-27. PubMed ID: 8711497
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF.
    Semin Oncol; 2000 Jun 15; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [Abstract] [Full Text] [Related]

  • 12. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 13. The role of paclitaxel in the management of patients with carcinoma of the cervix.
    Thigpen T, Vance R, Khansur T, Malamud F.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 2):S2-41-S2-46. PubMed ID: 9045336
    [Abstract] [Full Text] [Related]

  • 14. Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
    Belani CP.
    J Natl Compr Canc Netw; 2004 Sep 15; 2 Suppl 2():S10-22. PubMed ID: 19780242
    [Abstract] [Full Text] [Related]

  • 15. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D, Pectasides M, Economopoulos T.
    Cancer Treat Rev; 2006 Oct 15; 32(6):456-70. PubMed ID: 16935429
    [Abstract] [Full Text] [Related]

  • 16. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Morrissey LH, Scullin DC, Houston GA, Prasthofer EF, Gray JR, Burris HA, Greco FA.
    Cancer; 2002 May 01; 94(9):2426-33. PubMed ID: 12033195
    [Abstract] [Full Text] [Related]

  • 17. The role of paclitaxel in the therapy of bladder cancer.
    Roth BJ.
    Semin Oncol; 1995 Oct 01; 22(5 Suppl 12):33-40. PubMed ID: 7481859
    [Abstract] [Full Text] [Related]

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 19. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
    Cmelak AJ, Murphy BA, Burkey B, Douglas S, Shyr Y, Netterville J.
    Head Neck; 2007 Apr 01; 29(4):315-24. PubMed ID: 17252600
    [Abstract] [Full Text] [Related]

  • 20. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF.
    J Natl Compr Canc Netw; 2004 Sep 01; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.